Disruption of the blood-brain barrier in parkinson's disease: curse or route to a cure?
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
The vertebrate blood-brain barrier (BBB) is critical for ensuring the maintenance of brain homeostasis, whilst protecting the brain against toxic insults. Various pathological events disrupt BBB integrity, holding several important clinical implications. In instances where the normal mechanisms controlling passage of substances into the brain are compromised, these could sensitize or even worsen endogenous pathological conditions. Recognition has grown recently that patients diagnosed with Parkinson's disease (PD) present with concurrent medical problems, including cerebrovascular lesions. However, cerebrovascular disturbances may also result from PD-related disease processes; the pathological mechanisms which could entail interaction between environment-derived and genetic factors. The current review addresses the accumulation of studies aimed at better understanding the series of processes affecting the neurovascular unit in human Parkinsonism, due in part to the BBB presenting as a formidable opponent in the effective delivery of therapeutics that have shown promise as therapeutic strategies for treating aspects of PD when tested in vitro.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280 · cited 1×
“However, under circumstances of a leaky BBB this can have deleterious effects on perivascular astrocytes and neurons, which may contribute to slow neurodegenerative changes (11).”
Blood–brain barrier dysfunction in parkinsonian midbrain in vivo
Kortekaas, R., Leenders, K. L., van Oostrom, J. C. H., Vaalburg, W., Bart, J., Willemsen, A. T. M., & Hendrikse, N. H. (2005) · Annals of Neurology · doi:10.1002/ana.20369 · Cited by 733
Delivery of therapeutic agents to the central nervous system: the problems and the possibilities
Begley, D. J. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.08.001 · Cited by 679
Wilson, B., Samanta, M. K., Santhi, K., Kumar, K. P. S., Paramakrishnan, N., & Suresh, B. (2008) · Brain Research · doi:10.1016/j.brainres.2008.01.039 · Cited by 363
6-Hydroxydopamine-induced alterations in blood-brain barrier permeability
Carvey, P. M., Zhao, C. H., Hendey, B., Lum, H., Trachtenberg, J., Desai, B. S., Snyder, J., Zhu, Y. G., & Ling, Z. D. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.04281.x · Cited by 218 · cited 1×
“Data from another study indicated that expression of integrins reflect the level of angiogenesis in patients and in a reliable toxin-induced animal model of PD (33).”
Caffeine protects against MPTP‐induced blood‐brain barrier dysfunction in mouse striatum
Chen, X., Lan, X., Roche, I., Liu, R., & Geiger, J. D. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05697.x · Cited by 189 · cited 1×
“In other work, Chen and co-workers (46) revealed decreased expression of the TJ proteins ZO-1 and occludin in the striatum, with this decrease that was seen to associate with disruption of the BBB in an MPTP-induced mouse model of PD.”
Furuno, T., Landi, M.-T., Ceroni, M., Caporaso, N., Bernucci, I., Nappi, G., Martignoni, E., Schaeffeler, E., Eichelbaum, M., Schwab, M., et al. (2002) · Pharmacogenetics · doi:10.1097/00008571-200210000-00004 · Cited by 178
Desai Bradaric, B., Patel, A., Schneider, J. A., Carvey, P. M., & Hendey, B. (2012) · Journal of Neural Transmission · doi:10.1007/s00702-011-0684-8 · Cited by 139 · cited 1×
“On the other hand, several studies have reported detecting angiogenic activity in PD-affected regions, including the basal ganglia (29, 30).”
Cited by
Saraiva, C., Praça, C., Ferreira, R., Santos, T., Ferreira, L., & Bernardino, L. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.05.044 · Cited by 1,609
“In other cases, especially in chronic neurodegenerative conditions like AD and PD, it remains unclear if it is a downstream process or if it plays a role in disease onset and development [74,75].”
BackgroundLamptey, R. N. L., Chaulagain, B., Trivedi, R., Gothwal, A., Layek, B., & Singh, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031851 · Cited by 900
Blood–brain barrier and intestinal epithelial barrier alterations in autism spectrum disorders
Fiorentino, M., Sapone, A., Senger, S., Camhi, S. S., Kadzielski, S. M., Buie, T. M., Kelly, D. L., Cascella, N., & Fasano, A. (2016) · Molecular Autism · doi:10.1186/s13229-016-0110-z · Cited by 494
Astrocytic modulation of blood brain barrier: perspectives on Parkinson’s disease
Cabezas, R., Ãvila, M., Gonzalez, J., El-Bachá, R. S., Báez, E., GarcÃa-Segura, L. M., Jurado Coronel, J. C., Capani, F., Cardona-Gomez, G. P., & Barreto, G. E. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00211 · Cited by 449
Role of Blood-Brain Barrier in Alzheimer’s Disease
Cai, Z., Qiao, P.-F., Wan, C.-Q., Cai, M., Zhou, N.-K., & Li, Q. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-180098 · Cited by 370
“In addition, dysfunction of the BBB is also 133 involved in a wide range of neurological disorders 134 including stroke [23, 24], immune-neurological dis135 eases [25, 26], and neurodegenerative diseases such 136 as AD [27], Parkinson’s disease [27, 28], and multiple 137 system atrophy [29, 30].”
Metadata
- Authors
- Lee, H.
- Venue
- Frontiers in Bioscience
- Publisher
- IMR Press
- Published
- 2014
- Volume
- 19
- Issue
- 2
- Pages
- 272
- ISSN
- 1093-4715 (ISSN-L)
- 1093-9946
- DOI
- 10.2741/4206
- OpenAlex
- W1994624114
- Cited by
- 96
- References
- 8
- FWCI
- 4.07
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.